Grant: Master's Award: Canada Graduate Scholarships
McMaster University
$17,500.00
The Canada lymph node sonographic score as an evaluation of mediastinal lymph node malignancy for lung cancer: a feasibility study
EF 2018-19
Résumé
For clinical stage I Non-Small Cell Lung Cancer, surgical resection is usually the preferred method of treatment. However, to confirm patients are eligible for surgery, current guidelines mandate preoperative mediastinal lymph node (LN) staging through Endobronchial Ultrasound (EBUS). Unfortunately, up to 42% of biopsies conducted during EBUS provide inconclusive pathology results. This is especially true in patients with benign appearing LNs on preoperative CT or PET/CT scans. To improve the accuracy of mediastinal staging for those with negative PET/CT scans, researchers have created the Canada Lymph Node Score (CLNS). The CLNS is a four-point score based on the presence of four ultrasonographic features observed during EBUS. Together these features form a criteria of malignancy for the LN. Scores from 0 to 2 out of 4 imply low chance of malignancy in LN, while scores of 3 to 4 out of 4 describe high chance of malignancy. If a LN appears benign on PET/CT and its CLNS is less or equal to 2, then it is considered “triple negative”. For "triple negative" LNs, we hypothesize that they do not need to be biopsied because there is a very low probability of malignancy (less than 5% chance). To test the proposed hypothesis, a randomized control trial (RCT) is required. However, prior to warranting such a large scale trial, a feasibility study is needed to determine the adaptability of the CLNS within clinical setting. This study aims to evaluate the recruitment rate and differences in frequency of biopsies, procedure length, amount of sedation given, number of samples obtained, costs and diagnostic results between systematic sampling and targeted sampling of LNs. With these outcomes a better understanding of the practicability of this novel score will be achieved.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
411298
Name
Sullivan Kerrie
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
The Canada lymph node sonographic score as an evaluation of mediastinal lymph node malignancy for lung cancer: a feasibility study
Programtype2
Studentship Programs
Orgnameinp2
McMaster University
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Randomized Control Trial; Ebus; Endoscopy; Feasibility; Lung Cancer; Lymph Nodes; Malignancy Predictor; Mediastinal Staging; Novel Score; Ultrasonographic Features
Abstract
For clinical stage I Non-Small Cell Lung Cancer, surgical resection is usually the preferred method of treatment. However, to confirm patients are eligible for surgery, current guidelines mandate preoperative mediastinal lymph node (LN) staging through Endobronchial Ultrasound (EBUS). Unfortunately, up to 42% of biopsies conducted during EBUS provide inconclusive pathology results. This is especially true in patients with benign appearing LNs on preoperative CT or PET/CT scans. To improve the accuracy of mediastinal staging for those with negative PET/CT scans, researchers have created the Canada Lymph Node Score (CLNS). The CLNS is a four-point score based on the presence of four ultrasonographic features observed during EBUS. Together these features form a criteria of malignancy for the LN. Scores from 0 to 2 out of 4 imply low chance of malignancy in LN, while scores of 3 to 4 out of 4 describe high chance of malignancy. If a LN appears benign on PET/CT and its CLNS is less or equal to 2, then it is considered “triple negative”. For "triple negative" LNs, we hypothesize that they do not need to be biopsied because there is a very low probability of malignancy (less than 5% chance). To test the proposed hypothesis, a randomized control trial (RCT) is required. However, prior to warranting such a large scale trial, a feasibility study is needed to determine the adaptability of the CLNS within clinical setting. This study aims to evaluate the recruitment rate and differences in frequency of biopsies, procedure length, amount of sedation given, number of samples obtained, costs and diagnostic results between systematic sampling and targeted sampling of LNs. With these outcomes a better understanding of the practicability of this novel score will be achieved.
Competitiondate
201812
Approvedterm2
1 yr 0 mth
Pinamesdelim
Sullivan, Kerrie
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~